Table 1.
Infant and maternal characteristics for HIV-exposed uninfected infants whose mothers were prescribed tenofovir disoproxil fumarate (TDF) for at least 8 weeks in the third trimester of pregnancy (n=58)
| Infant Characteristics | N (%), median (range) | |
|---|---|---|
| Black/African American race | 34 (59%) | |
| Hispanic ethnicity | 17 (29%) | |
| Male | 37 (64%) | |
| Cumulative prenatal TDF exposure duration (weeks) | 25.7 (8 – 41) | |
| Gestational age (weeks) | 38 (36 – 41) | |
| Gestational age < 37 weeks | 1 (1.7%) | |
| Age at DXA scan (days) | 14 (7 – 29) | |
|
| ||
| Maternal Characteristics | N (%), median (range) | |
|
| ||
| Age at delivery (years) | 30.5 (17.5 – 45.0) | |
| Education <high school | 20 (34%) | |
| Annual income <$10,000 | 35 (60%) | |
| Marital status | Married | 18 (31%) |
| Separated/divorced | 5 (9%) | |
| Single, never married | 35 (60%) | |
| Tobacco use in pregnancya | 11 (19%) | |
| Alcohol use in pregnancya | 4 (7%) | |
| Illicit drug use in pregnancya | 3 (5%) | |
| Any substance use during pregnancya | 15 (26%) | |
| Pre-pregnancy body-mass-index, BMI, (kg/m2)b | 28.7 (17.2 – 47.7) | |
| CD4 count (cells/μL) median (range)c | First trimester | 455 (8 – 1,417) |
| Second trimester | 445 (103 – 1,059) | |
| Third trimester | 76 (50 – 51,286) | |
| HIV RNA (copies/mL) median (range)d | First trimester | 363 (50 – 87,096) |
| Second trimester | 324 (50 – 109,648) | |
| Third trimester | 76 (50 – 51,286) | |
| HIV RNA <50 copies/mL (%)d | First trimester | 21.6% |
| Second trimester | 14.6% | |
| Third trimester | 29.4% | |
| Maternal TDF regimen with atazanavir | 31 (53%) | |
| Maternal TDF regimen with any protease inhibitor | 49 (85%) | |
| Most prevalent regimense | TDF/emtricitabine/atazanavir/ritonavir | 27 (47%) |
| TDF/emtricitabine/darunavir/ritonavir | 10 (17%) | |
| TDF/emtricitabine/raltegravir | 5 (9%) | |
| TDF/emtricitabine/lopinavir/ritonavir | 5 (9%) | |
Unknown data for 1 participant; any substance use during pregnancy included alcohol, tobacco, or illicit drug use (marijuana, cocaine, heroin, opium, PCP, or MDMA).34
Unknown data for 7 participants
Unknown data for 16 participants in the first trimester, 22 participants in the second trimester, and 4 in the third trimester
Unknown data for 21 participants in the first trimester, 17 participants in the second trimester, and 7 in the third trimester
Most prevalent regimens at delivery; other TDF-containing regimens at delivery (n=11) were unique with a frequency of only 1 woman